Stay updated on Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Sign up to get notified when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.

Latest updates to the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision label updated from v3.3.1 to v3.3.2. No visible changes to the study details or page content.SummaryDifference0.0%

- Check21 days agoChange DetectedThe page shows a new revision label, updating from v3.2.0 to v3.3.1. This appears to be a minor system update with no changes to the study details, eligibility, or outcomes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check29 days agoChange DetectedRemoved the general funding-status notice about government funding and NIH operating status from the page. This removes guidance on updates about funding delays and where to check operating status.SummaryDifference0.3%

- Check43 days agoChange DetectedCore study information remains unchanged between the two screenshots; there are no updates to the title, condition, interventions, outcomes, eligibility, enrollment, or locations. Only minor formatting/layout differences are observed.SummaryDifference0.3%

- Check71 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference5%

- Check79 days agoChange DetectedUpdated the page revision from v3.0.2 to v3.1.0, indicating a new software release or document update. No changes to core content, pricing, or stock are evident.SummaryDifference0.1%

Stay in the know with updates to Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase 3 Daclatasvir/Asunaprevir in Hepatitis C Clinical Trial page.